INTRODUCTION
Carbohydrate-receptor interactions participate in numerous cell-cell recognition events in eukaryotes (1) (2) (3) (4) . Of the nine monosaccharides that constitute mammalian polysaccharides, the common terminal residue sialic acid stands out as a major determinant of cell-cell interactions.
Sialic acid is a component of sialyl Lewis x (sLe x ), a tetrasaccharide that binds the selectin family of adhesion molecules and initiates inflammatory leukocyte adhesion (5) . Sialic acid is also the major binding determinant of Siglecs, a family of sialic acid-binding lectins that are involved in many processes including B-cell signaling and activation (6) .
Because of the prominent role of sialic acid in cell surface recognition, there is considerable interest in the regulatory mechanisms that control its biosynthesis and presentation on the cell surface ( Figure 1 ) (7). The first committed intermediate in the biosynthesis of sialic acid is N-acetylmannosamine (ManNAc), which is phosphorylated by ManNAc 6-kinase (8, 9 ) to initiate sialic acid biosynthesis in the cytosol. The subsequent action of sialic acid synthase (10), followed by an unknown phosphatase, yields sialic acid, which is then transformed into CMPsialic acid by CMP-sialic acid synthetase in the nucleus (11, 12) . After transport into the Golgi compartment, the sialyltransferases utilize this substrate to sialylate the terminal position of oligosaccharide chains. Transcriptional regulation of sialyltransferases is one mechanism for controlling the production of certain sialylated epitopes such as polysialic acid (13) , sLe x (5) or α-2,6-linked sialyllactosamine (6) .
The overall production of sialic acid in mammalian cells appears to be regulated by the availability of ManNAc which, in principle, can be synthesized through two possible routes.
UDP-N-Acetylglucosamine (UDP-GlcNAc) 2-epimerase ( Figure 1 ) catalyzes the conversion of UDP-GlcNAc to ManNAc and has been implicated as a major source of ManNAc in mammalian cells (14) (15) (16) . High levels of CMP-sialic acid inhibit UDP-GlcNAc 2-epimerase, thereby reducing flux in the sialic acid biosynthetic pathway (17) . A second enzyme, GlcNAc 2-epimerase, can also produce ManNAc by catalyzing the reversible epimerization of GlcNAc to Role of GlcNAc 2-epimerase 4
ManNAc (18) (19) (20) . However, GlcNAc is thermodynamically favored with an equilibrium ratio of 3.9:1 (21). Thus, it is possible that GlcNAc 2-epimerase functions to divert ManNAc away from sialic acid biosynthesis and into other glycosylation or glycolytic pathways. Additionally, human GlcNAc 2-epimerase binds the protease renin (22) , but as of yet no functional significance for this interaction has been demonstrated (23) . In summary, the role of UDPGlcNAc 2-epimerase in the biosynthesis of sialic acid has been clearly established, but the cellular role of GlcNAc 2-epimerase remains unclear.
Northern analysis of the mRNAs encoding these epimerases has revealed some differences in their tissue distribution in mice. UDP-GlcNAc 2-epimerase is highly expressed in the liver (9,24), while GlcNAc 2-epimerase is highly expressed in the kidney (23) . The enzymes do appear to have some overlapping tissue distribution, however, suggesting either that one enzyme is redundant or the functions they perform are distinct.
To investigate the function of GlcNAc 2-epimerase in cells, we identified a cell line lacking the enzyme, introduced the gene into these cells and studied the effects of GlcNAc 2-epimerase expression on sialic acid biosynthetic flux. We found that GlcNAc 2-epimerase expression suppressed sialic acid production in response to exogenous addition of ManNAc or ManNAc analogs. Furthermore, guided by a proposed chemical mechanism (21), we prepared two novel substrate-based inhibitors of GlcNAc 2-epimerase and demonstrated that one of these inhibitors functions within cells to block the action of the enzyme. Using the inhibitor as a tool, we confirmed that the phenotype resulting from GlcNAc 2-epimerase expression was indeed due to direct action of the enzyme. Based on these data, we propose that GlcNAc 2-epimerase plays a catabolic role in sialic acid metabolism. Calbiochem. Cell densities were determined using a Coulter Z2 cell counter. Flow cytometry data were acquired using a Coulter EPICS XL-MCL flow cytometer or a BD Biosciences
FACSCalibur flow cytometer equipped with a 488 nm argon laser. For flow cytometry experiments, 10,000 live cells were analyzed and all data points were collected in triplicate.
All chemical reagents were obtained from commercial suppliers and used without further purification unless otherwise noted. All NMR spectra were measured with a Bruker AMX-300, AMX-400 or DRX-500 MHz spectrometer as noted. All coupling constants (J) are reported in Hz. Mass spectral data were obtained from the UC Berkeley Mass Spectrometry Laboratory.
Reversed-phase HPLC was performed using a Rainin Dynamax SD-200 HPLC system with 220 nm detection on a Microsorb C 18 analytical column (4.6 x 250 mm) at a flow rate of 1.0 ml/min or a preparative column (25 x 250 mm) at a flow rate of 20 ml/min. Ac 4 ManLev (25), Ac 4 ManNAz (26) and compound 2 (27) were synthesized as previously described.
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Expression of GlcNAc 2-epimerase in Jurkat cells
For mammalian expression, the GlcNAc 2-epimerase gene was cloned into the pcDNA5/FRT vector, a component of the FlpIn system, by digestion of pUKHRB6 (20) and pcDNA5/FRT with EcoR I and subsequent ligation with T4 DNA ligase. The correct product was confirmed by DNA sequencing and the vector was denoted pSJLG2E/FRT. The gene encoding the red fluorescent protein (dsRed) was also cloned into pcDNA5/FRT. The vectors pcDNA5/FRT and pDsRed2-N1 were digested with Hind III and Not I and the gene encoding dsRed was ligated into pcDNA5/FRT with T4 DNA ligase. The correct product was confirmed by DNA sequencing and the vector was denoted pSJLRFP/FRT.
Jurkat cell lines stably expressing GlcNAc 2-epimerase were generated with the FlpIn system according to the manufacturer's instructions. Briefly, Jurkat cells were transfected with pFRT/lacZeo using Lipofectamine PLUS. After selection using Zeocin, stable transfectants were isolated that contain Flp recombinase sites flanking the Zeocin resistance gene. Clonal populations were isolated using "feeder" Jurkat cells as previously described (28) Jurkat and Jurkat-derived cell lines were maintained in a 5.0% CO 2 , water-saturated atmosphere at 37 ºC and grown in RPMI-1640 media supplemented with penicillin (100 units/ml) and streptomycin (0.1 mg/ml). Wt* cells were grown in the presence of Zeocin (100 µg/ml) and G2E* cells were grown in the presence of Hygromycin (300 µg/ml). Typically, both 7 cell lines were grown in T-25 flasks and cell densities were maintained between 2.0 x 10 5 and 1.6
x 10 6 cells/ml.
RT-PCR on wt* and G2E* cells
Messenger RNA from 5.0 x 10 6 of Jurkat, wt* and G2E* cells was isolated using the Micro-FastTrack 2.0 mRNA Isolation kit according to the manufacturer's instructions. cDNA was synthesized using the SuperScript First-Strand Synthesis kit and oligo dT primers. The 
Flow cytometry
Cells were seeded at a density of 2.0 x 10 5 cells/ml and incubated for three days with the compounds indicated. Cells were then washed and stained with either biotin hydrazide and FITC-avidin to detect ketones (29) , or phosphine-FLAG and anti-FLAG-FITC to detect azides (30) . For lectin staining, wt* and G2E* cells were washed twice with wash buffer (PBS, pH 7.1, 
Periodate-resorcinol determination of sialic acid concentration
Wt* or G2E* cells were incubated with the indicated substrate or with no substrate. Cells were grown to a density between 6.0 x 10 5 and 9.0 x 10 5 cells/ml over three days and the periodate-resorcinol assay was performed as described (28, 31) .
Synthesis of compound 1
Hydroxylamine hydrochloride (4.0 g, 0.057 mol) and sodium methoxide (3.0 g, 0.057 mol) were stirred in methanol for 30 min. The resulting white salts were removed by filtration. 
Synthesis of compound 3
Acetic anhydride (5.0 ml, 0.055 mol) was added to a solution of 2 (1.0 g, 0.0045 mol) in pyridine (10 ml) and the reaction was stirred overnight at room temperature. The solution was concentrated, dissolved in CHCl 3 and washed with 1.0 M HCl, NaHCO 3 and saturated NaCl.
The organic phase was dried over MgSO 4 , filtered and concentrated to give the crude product (0.64 g, 33% 
Protein expression and purification
For bacterial expression, the human GlcNAc 2-epimerase gene was cloned into pET28b(+). The GlcNAc 2-epimerase gene was amplified by PCR using Pfu DNA polymerase, Upon ligation with T4 DNA ligase, the correct C-terminus of the GlcNAc 2-epimerase gene was installed. DNA sequencing of the resulting vector, pSJL737, confirmed this result.
The vector pSJL737 was transformed into the E. coli strain BL21(DE3) and expression of 
Colorimetric assay for GlcNAc 2-epimerase
The colorimetric assay to detect the epimerization of ManNAc by GlcNAc 2-epimerase was performed as described (32) , except that the enzymatic reactions were monitored continuously on a Molecular Devices SpectraMax 190 spectrophotometer to acquire initial rates.
Trend lines for inhibition by 1 and 2 were determined from non-linear regression analysis using the program GraFit 4.0 and the data were fit to a competitive inhibition model using the nonlinear regression analysis program, SAS. Trend lines did not converge to fit a noncompetitive pattern for either compound. There was a small background rate that could be attributed to the side reaction of ManNAc with the coupling enzymes, as previously reported (32) . In all assays this background signal was subtracted to establish the actual rate of the reaction. In addition, at the highest inhibitor concentrations and lowest substrate concentrations, there was a significant background signal that was attributed to reaction of the inhibitor directly with the coupling enzymes. This value was subtracted but likely contributes some error to the rates measured using these data points. 
H NMR assay for GlcNAc 2-epimerase activity

RESULTS
Introduction of GlcNAc 2-epimerase into human cells
Analysis of mRNA from the human T cell lymphoma line Jurkat by RT-PCR showed no detectable message for GlcNAc 2-epimerase, suggesting that ManNAc is produced exclusively by UDP-GlcNAc 2-epimerase in these cells. Accordingly, the mRNA encoding UDP-GlcNAc 2-epimerase was observed by RT-PCR (data not shown).
To achieve stable expression of GlcNAc 2-epimerase in Jurkat cells, we used the two- We have previously found that the size of the N-acyl group on ManNAc derivatives can affect the efficiency of unnatural sialic acid biosynthesis in cells (37) and substrate activity with isolated enzymes in vitro (38) . Accordingly, we postulated that GlcNAc 2-epimerase catalyzes the epimerization of ManNAz to the corresponding gluco analog more efficiently than ManLev.
To address this experimentally, we developed an in vitro 1 H NMR assay to measure the relative rates of the GlcNAc 2-epimerase-catalyzed reaction with the two unnatural substrates. As shown in Table 1 , the enzyme epimerizes ManNAz 345 times more rapidly than ManLev, and both substrates react more slowly than ManNAc.
The effect of GlcNAc 2-epimerase on intracellular free sialic acid concentrations
To investigate the effect of GlcNAc 2-epimerase on the flux of natural sialic acid biosynthesis, we analyzed free sialic acid content in wt* and G2E* cells. Levels of glycoconjugate-bound and total sialic acid can be measured using the periodate-resorcinol assay and the level of free sialic acid can be determined by subtracting the former from the latter (31).
The level of free sialic acid in untreated Jurkat cells is close to the detection limit of the assay and is difficult to measure reproducibly. Nonetheless, G2E* cells appeared to have lower concentrations of free sialic acid than wt* cells ( Figure 5 ).
More reliable measurements were obtained by the addition of ManNAc, which increases the amount of free sialic acid in the cell well above the limit of detection. When both cell lines were treated with 10 mM ManNAc, G2E* cells clearly produced less sialic acid than wt* cells ( Figure 5 ). Thus, in the presence of excess ManNAc, GlcNAc 2-epimerase acts to lower free sialic acid levels, presumably by diverting ManNAc to GlcNAc. The Jurkat cell lines were also both incubated with 10 mM GlcNAc and analyzed for the effect on sialic acid content. The addition of GlcNAc did not measurably increase the level of sialic acid in G2E* cells above that in wt* cells ( Figure 5 ), suggesting that intracellular ManNAc concentrations did not differ significantly between the two cell lines. To rule out the possibility that the different effects of ManNAc and GlcNAc on sialic acid production were due to differential uptake by the cells, we performed the same experiment with the peracetylated derivatives. These compounds should equally penetrate cell membranes by passive diffusion (36) . The peracetylated compounds had the same relative effects on sialic acid content in wt* and G2E* cells as observed with free ManNAc and GlcNAc (data not shown).
Substrate-based inhibitor of GlcNAc 2-epimerase
The previous experiments establish that GlcNAc 2-epimerase expression correlates with a reduction in sialic acid biosynthesis. In order to confirm that this reduction was the direct result of enzyme activity, we designed an inhibitor of GlcNAc 2-epimerase for use in cellular studies.
A mechanism describing the interconversion of GlcNAc and ManNAc by GlcNAc 2-epimerase was recently proposed by Samuel and Tanner ( Figure 6A ) (21) Figure 6B ) and adapted a published enzyme-coupled colorimetric assay for GlcNAc 2-epimerase to measure their inhibitory activity.
The assay detects the production of GlcNAc by enzymatic oxidation of the C-6 hydroxyl group and concomitant production of hydrogen peroxide, which is subsequently consumed in a chromogenic peroxidase reaction (32) . For ease of analysis we modified the assay to monitor the reaction continuously.
The value of K M obtained for ManNAc (4.3 mM) was close to the literature value (13.2 mM) obtained using the endpoint assay (46) . We then measured the inhibition constants (K I ) of 1 and 2 to be 90 µM and 109 µM, respectively. By varying the concentrations of substrate and inhibitor, we obtained kinetic data consistent with a competitive inhibition mechanism for both 1 and 2, indicating that both analogs compete with ManNAc for the active site ( Figure 7 ). To make an inhibitor useful in cell culture (36), compound 2 was acetylated to form compound 3 ( Figure 6B ).
GlcNAc 2-epimerase inhibitor is active in cells
Compound 3 was used to confirm that GlcNAc 2-epimerase activity was responsible for the reduced conversion of Ac 4 ManLev to SiaLev in G2E* cells compared to wt* cells. As shown in Figure 8 , compound 3 reverses the effect of GlcNAc 2-epimerase in a dose-dependent fashion, nearly restoring unnatural sialic acid biosynthesis to wt* levels at 200 µM. Importantly, the production of SiaLev in wt* cells was not significantly affected by the addition of 3.
Finally, we incubated wt* and G2E* cells with ManNAc in the presence and absence of compound 3 and analyzed free sialic acid levels using the periodate-resorcinol assay (Figure 9 ).
Although the sialic acid level in G2E* cells was still lower than that in wt* cells, the differential was significantly reduced by the GlcNAc 2-epimerase inhibitor (100 µM). Thus, the inhibitor reverses the low sialic acid phenotype characteristic of G2E* cells, confirming that the enzyme is directly responsible for that phenotype.
DISCUSSION
To investigate the effect of GlcNAc 2-epimerase on intracellular metabolic flux within the sialic acid pathway, we initially analyzed cell surface sialic acid expression. Sialic acidbinding lectins revealed little about the changes in sialic acid metabolism resulting from GlcNAc 2-epimerase expression in Jurkat cells. However, we were able to observe an effect on sialic acid biosynthesis by using unnatural metabolic substrates and by measurements of intracellular sialic acid levels. G2E* cells, which express GlcNAc 2-epimerase, were unable to convert two unnatural ManNAc analogs (Ac 4 ManLev and Ac 4 ManNAz) to the corresponding sialosides (SiaLev and SiaNAz) at levels comparable to wt* cells. This observation is consistent with epimerization of the ManNAc analogs to the corresponding GlcNAc analogs, and consequently, diversion from the sialic acid pathway. GlcNAc derivatives that are produced in this fashion could be utilized in other metabolic pathways that do not contribute to cell surface fluorescence, or they may be dead-end biosynthetic intermediates. This model for the effect of GlcNAc 2-epimerase on sialic acid biosynthesis is summarized in Figure 10A .
Alternatively, it may be possible that G2E* cells produce higher levels of ManNAc than wt* cells due to epimerization of GlcNAc, a model summarized in Figure 10B . Indeed, ManLev was previously used by our laboratory as a tool to select a Jurkat cell line containing mutations in the UDP-GlcNAc 2-epimerase gene that make the protein resistant to inhibition by CMP-sialic acid (28) . Lacking that regulatory mechanism, these cells overproduced ManNAc, which suppressed unnatural sialic acid expression by direct competition with ManLev. The models shown in Figure 10 are not mutually exclusive; GlcNAc 2-epimerase may perform either of these functions depending on the relative availabilities of GlcNAc and ManNAc in the cell. Since the inhibitors were designed to mimic the ring-opened form of GlcNAc, this lends support to the proposed mechanism in Figure 6A It is possible that the primary function of GlcNAc 2-epimerase is to divert metabolic flux from sialic acid biosynthesis into other pathways reliant on GlcNAc or UDP-GlcNAc.
Numerous glycoproteins and proteoglycans include GlcNAc as a component, and several cytosolic and nuclear proteins are modified with β-O-GlcNAc in a possible regulatory fashion (47, 48) . Increases in cellular GlcNAc may affect the flux in these pathways. Alternatively, phosphorylation of GlcNAc followed by deacetylation of GlcNAc 6-phosphate to glucosamine 6-phosphate generates a substrate for glycolysis (49) . It is possible that GlcNAc 2-epimerase serves to increase glycolytic flux at the expense of protein glycosylation.
We conclude that GlcNAc 2-epimerase catalyzes the conversion of ManNAc (and 
